Fig. 4.

ApoA-I and apoA-I mimetic peptides reduce viability and inhibit ID8 cell proliferation, and also reduce cell viability of cis-platinum–resistant human ovarian cancer cell lines in vitro. ID8 cells were cultured as described in Materials and Methods, and incubated with either apoA-I or apoA-II (100 μg/mL; 3.57 or 5.75 μM, respectively) or apoA-I mimetic peptides (L-5F, L-4F, or sc-4F at a concentration of 10 μg/mL; 4.11 μM for L-5F, and 4.12 μM for L-4F and sc-4F) for 48 h. (A, C, and E) Cells were assayed for viability using the MTS assay kit. (B and D) BrdU incorporation was analyzed as described in Materials and Methods. Data are represented as the mean ± SD of the percent of control cells. All experiments were performed in triplicate and each assay was carried out in quadruplicates. (E) OVCAR5, SKOV3, OV2008, and A2780 cell lines were cultured as described in Materials and Methods and were either untreated (open bars) or treated with 10 μg/mL (4.12 μM) of L-4F (closed bars).